Clinical and hormonal response of patients with galactorrhea syndrome treated with bromergocryptine.
Tne patients with galactorrhea syndrome were treated with two different daily dosages (5 mg and 7.5 mg) of Bromergocryptine. The 5 mg daily dosage often did not produce the desired hormonal and clinical response. Five patients were treated with this regimen for 38 to 90 days, with treatment extending over more than one menstrual cycle. However, the 7.5 mg daily dosage resulted in complete cessation of galactorrhea in all patients, restoration of menstrual cycles in five patients, and pregnancies in four patients. Disappearance of lactation proved to be a very good indicator of the general responsiveness of patients. Nausea, vomiting, and occasional dizziness were side effects of the drug. The case histories and hormonal findings of four typical patients are reported.
D001971:Bromocriptine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005687:Galactorrhea / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007775:Lactation Disorders / Q000188:drug therapy*; D008598:Menstruation; D011247:Pregnancy; D013577:Syndrome
D001971:Bromocriptine